Elom-080: New hope for Covid 19 patients in the family practice!

Elom-080: New hope for Covid 19 patients in the family practice!

Laimgrubengasse 10, 1060 Wien, Österreich - On February 12, 2025, Pohl-Boskamp presented the results of the Covari-2 study, which examined the effectiveness of the vegetable active ingredient ELOM-080 in the treatment of covid 19 patients in outpatient care. Like Pohl-Boskamp reported , Wiesen Prof. Dr. Michael Dreher from the University Hospital Aachen and his team would like to expand that the new data expand the findings from the first Covari study. The aim was to investigate 121 patients aged 18 to 60, who received either Elom-080 or a placebo during a 14-day treatment period. The key to treatment was to improve the mucociliary clearance (MCC), which is often restricted in COVID 19 patients.

study results and highlights

In primary analysis, there were initially no significant differences between the two groups, which is due to the great heterogeneity of the patients. However, post-hoc analyzes showed that patients with suspected a disturbed MCC benefited from Elom-080. There was a significant reduction in coughing fits (p = 0.007) and a decline in shortness of breath under load (p = 0.0252). In addition, the patients showed a faster symptomist from 1 to 3 days, as

Prof. Dr. Dreher said: "The results emphasize the importance of targeted therapy in outpatient care, in particular with regard to heavily stressful symptoms such as cough and shortness of breath." This emphasizes Elom-080 as a potential component in the therapy of Covid-19 in the outpatient sector, which is of great clinical relevance in view of the lack of market registrations for treatments in this patient group.